Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > Chuikyo Debate on FY2026 Drug Pricing Reform
Chuikyo Debate on FY2026 Drug Pricing Reform
-
Generic Firms Push Reform to Ensure Stability, Wholesalers Seek End to Off-Year Cuts
September 18, 2025
-
FIRM Calls for Pricing Overhaul to Reflect Unique Benefits of Regenerative Therapies
September 18, 2025
-
FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
September 18, 2025
-
Tensions Flare at Chuikyo over Premiums for Generic Dispensing
September 16, 2025
-
Japan to Discuss Negative Margins, Packaging Optimization towards FY2026 Reform
August 8, 2025
-
Medical Device Pricing Body Urges Clearer Evaluation Criteria for SaMDs Reimbursement
August 8, 2025
-
Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
-
DPO Floats Premium Expansion, Relaxed Criteria towards FY2026 Reform
August 7, 2025
-
Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
July 17, 2025
-
Generic and Wholesaler Groups Call for Pricing Reforms to Reflect Inflationary Pressures
July 11, 2025
-
16 Drugs Enter Japan Trials after Pro-Innovation Reform: Industry Poll
July 10, 2025
-
Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
July 10, 2025
-
Trade Groups Urge Pricing Overhaul for Regenerative Medicines, Biotech Drugs
July 10, 2025
-
Japan Begins FY2026 Drug Pricing Reform Talks; Responses to Inflation, High-Cost Therapies on Agenda
June 26, 2025
-
Chuikyo OKs Drug Price Survey Plan for FY2026 Revision
June 26, 2025
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…